However, even for the exclusively EGFR-mutant advanced NSCLC patients, the median progression-free survival (PFS) was only 9–13 months for those who accepted first-line EGFR-TKI therapy [2–5]. Here, EGFR is linked to non-small cell lung carcinoma.